Browsing Centre for Cancer Prevention by Author "Szlosarek, PW"
Now showing items 1-3 of 3
-
BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification
Barnett, SE; Kenyani, J; Tripari, M; Butt, Z; Grosman, R; Querques, F; Shaw, L; Silva, LC; Goate, Z; Marciniak, SJ (2023) -
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
Zauderer, MG; Szlosarek, PW; Le Moulec, S; Popat, S; Taylor, P; Planchard, D; Scherpereel, A; Koczywas, M; Forster, M; Cameron, RB (2022) -
Role of 3'-Deoxy-3'-[18F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase.
Szyszko, TA; Dunn, JT; Phillips, MM; Bomalaski, J; Sheaff, MT; Ellis, S; Pike, L; Goh, V; Cook, GJR; Szlosarek, PW (2022-09)INTRODUCTION: Pegargiminase (ADI-PEG 20I) degrades arginine in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma (MPM) and NSCLC. Imaging with proliferation biomarker 3'-deoxy-3'-[18F] ...